Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has earned an average rating of “Moderate Buy” from the eight analysts that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $3.1667.

A number of brokerages recently issued reports on INO. HC Wainwright restated a “neutral” rating on shares of Inovio Pharmaceuticals in a research note on Thursday, August 13th. Piper Sandler reiterated an “overweight” rating and set a $4.00 price objective on shares of Inovio Pharmaceuticals in a research note on Monday, August 3rd. Wall Street Zen raised shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Zacks Research raised shares of Inovio Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, August 12th. Finally, Jefferies Financial Group raised shares of Inovio Pharmaceuticals from a “hold” rating to a “positive” rating and increased their price target for the stock from $1.80 to $3.00 in a research report on Thursday, August 13th.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in INO. AQR Capital Management LLC acquired a new stake in shares of Inovio Pharmaceuticals during the 1st quarter valued at approximately $120,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Inovio Pharmaceuticals by 39.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 5,894 shares during the period. Qube Research & Technologies Ltd bought a new stake in Inovio Pharmaceuticals during the second quarter valued at $234,000. Jane Street Group LLC increased its stake in Inovio Pharmaceuticals by 221.2% during the second quarter. Jane Street Group LLC now owns 39,683 shares of the biopharmaceutical company’s stock valued at $81,000 after purchasing an additional 27,329 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Inovio Pharmaceuticals by 1,667.1% during the third quarter. JPMorgan Chase & Co. now owns 65,206 shares of the biopharmaceutical company’s stock worth $153,000 after purchasing an additional 61,516 shares during the period. Institutional investors and hedge funds own 26.79% of the company’s stock.

Inovio Pharmaceuticals Price Performance

Shares of NASDAQ INO opened at $1.43 on Monday. Inovio Pharmaceuticals has a fifty-two week low of $0.56 and a fifty-two week high of $2.98. The business has a 50 day moving average price of $1.08 and a two-hundred day moving average price of $1.26. The firm has a market cap of $147.86 million, a PE ratio of -1.57 and a beta of 1.63.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its earnings results on Wednesday, August 12th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.15. On average, analysts anticipate that Inovio Pharmaceuticals will post -0.72 earnings per share for the current year.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.